Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pozdeutinurad - Arthrosi Therapeutics Australia

Next Previous
Drug Profile

Pozdeutinurad - Arthrosi Therapeutics Australia

Alternative Names: AR-882

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arthrosi Therapeutics Australia
  • Developer Arthrosi Therapeutics; Arthrosi Therapeutics Australia; Guangzhou Ruianbo Pharmaceutical Technology
  • Class Antigouts; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gout
  • Phase II/III Hyperuricaemia

Most Recent Events

  • 12 Jun 2025 Updated efficacy and adverse events data from the phase II AR882-203 trial in Gout released by Arthrosi Therapeutics
  • 05 Mar 2025 Arthrosi plans to initiate a pivotal phase III REDUCE 1 trial in Gout in first half of 2025
  • 26 Feb 2025 Arthrosi Therapeutics initiates a phase III trial for Gout in the US (PO) (NCT06846515)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top